CA Patent

CA2519658A1 — Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds

Assigned to Sanofi Aventis Deutschland GmbH · Expires 2004-10-07 · 22y expired

What this patent protects

The invention relates to compounds of formula I wherein R1 to R9 have the designations cited in the patent claims. Medicaments containing this type of compound can be used in the prevention or treatment of various illnesses. Said compounds can be used, inter alia, for renal disea…

USPTO Abstract

The invention relates to compounds of formula I wherein R1 to R9 have the designations cited in the patent claims. Medicaments containing this type of compound can be used in the prevention or treatment of various illnesses. Said compounds can be used, inter alia, for renal diseases such as acute or chronic kidney failure, for disturbances of the biliary function, for respiratory disturbances such as snoring or sleep apnoea, or for apoplexy.

Drugs covered by this patent

Patent Metadata

Patent number
CA2519658A1
Jurisdiction
CA
Classification
Expires
2004-10-07
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi Aventis Deutschland GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.